“2025 marked a year of significant progress for Compass, highlighted by our lead asset tovecimig successfully meeting the primary endpoint of overall response rate in the COMPANION-002 Phase 2/3 study in patients with biliary tract cancer. We are excited to report the results of the key secondary endpoints next month,” said Thomas Schuetz, MD, PhD, Chief Executive Officer and Vice Chairman of the Board of Directors. “The upcoming tovecimig PFS/OS data release could be transformational for the company, and we are looking forward to the new option it would bring for patients with biliary tract cancer.”
Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on CMPX:
- CMPX Upcoming Earnings Report: What to Expect?
- Buy Rating on Tovecimig Driven by Early Efficacy Signals and Differentiated Risk–Benefit Profile in Biliary Tract Carcinoma
- Compass Therapeutics Moves CTX-10726 Into the Clinic: What Early Investors Should Know
- 3 Strong Buy Stocks With 100%+ Upside, According to Top Analysts, 2/16/2026
- Craig-Hallum bullish on Compass Therapeutics, initiates with a Buy